KindredBio is focused on bringing innovative biologics and technologies to veterinary medicine to address unmet clinical needs and provide benefits to pets.
We identify biologics and targets that have been validated in humans and develop animal versions to treat and cure pets. We seek to leverage the investments that have been made in human pharmaceutical R&D to develop therapies for pets with lower risk, lower cost, and shorter time-to-market, compared to human drug development.
We believe KindredBio can deliver superior returns to investors because while the market sizes for pet drugs are about 2-fold to 10-fold smaller compared to human market sizes, the cost of development is 100-fold less.
World Class Team
KindredBio is one of the first pet biotechs in the world, and we have a world-class team including the former Head of Biotherapeutics Clinical Research at Genentech. We also have expertise in many cutting-edge antibody technologies. Because of the team, and because we do not outsource our clinical studies, we can move at a very rapid pace.
To contact investor relations, or to request an investor packet, please call 917.969.3438 or email IR@kindredbio.com.